Memory care will be big growth area in 2018, senior living leaders predict
By
Lois A. Bowers
Feb 14, 2018
Memory care will be the biggest growth area in senior living and long-term care in 2018, predict executives participating in Lancaster Pollard’s “2018 Seniors Housing and Care Survey,”...
Prevalence of LATE-NC explored in seniors, Alzheimer’s disease
Jun 20, 2022
Almost 40% of those with Alzheimer’s disease neuropathologic change had a limbic-predominant age-related TDP-43 encephalopathy neuropathologic change.
New Alzheimer’s disease drug delivers disappointing results
Jun 17, 2022
The trial was the first to test a drug meant to delay or halt mental decline in people who have a genetic predisposition.
Senior living community will ‘vigorously’ defend itself in wrongful termination lawsuit
By
Kimberly Bonvissuto
Jun 02, 2022
The owner of an Iowa assisted living and memory care community says the company will “vigorously” defend itself in a wrongful termination lawsuit from a former resident assistant who alleges she was...
Levetiracetam well-tolerated for Alzheimer’s disease
Oct 01, 2021
It does not improve primary outcome but did improve performance on certain cognitive tasks in those with epileptiform activity.
New CDC profile shares demographics of assisted living residents
By
Kimberly Bonvissuto
Sep 22, 2021
Bathing, walking and dressing are the most common activities of daily living that residents of assisted living or similar residential communities need help with, according to a new data brief from the...
FDA head asks for investigation into Alzheimer’s disease drug approval
Jul 12, 2021
The request follows reports that Biogen and the FDA held off-the-books meetings before the drug’s approval that may have violated FDA protocol.
Prediction model for brain age may help detect cognitive decline
Jul 01, 2021
Greater differences between predicted age based on brain MRI and actual age were seen in those with amnestic mild cognitive impairment versus healthy controls.
Lilly to seek FDA approval for new drug for Alzheimer’s disease
Jun 25, 2021
Donanemab already has received a ‘breakthrough therapy’ designation from the FDA.
ARIA described from clinical trials of aducanumab for Alzheimer’s disease
Dec 10, 2021
Amyloid-related imaging abnormalities-edema seen on brain MRI was the most common adverse event in participants receiving high-dose aducanumab (Aduhelm).